SCHEMBL30766151

SCHEMBL30766151

CC(Nc1cnc(-c2ccccc2F)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.37
LMNA P02545 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C9 P11712 1/20 0.35
PTGDR Q13258 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765981 0.95 LMNA (0.37) ELANELMNAALDH1A1HPGDCYP2C9
SCHEMBL31558470 0.95 LMNA (0.37) ELANELMNAALDH1A1HPGDCYP2C9
SCHEMBL30765454 0.93 ELANE (0.37) ELANECYP2C9PTGDRPTGDR2HDAC6
SCHEMBL30765745 0.92 ELANE (0.37) ELANELMNAALDH1A1HPGDCYP2C9
SCHEMBL31558409 0.92 POLB (0.36) ELANELMNAALDH1A1CYP2C9GABRP
SCHEMBL30765536 0.89 LMNA (0.34) ELANELMNAALDH1A1HPGDGABRP
SCHEMBL31558526 0.89 LMNA (0.34) ELANELMNAALDH1A1HPGDCYP2C9
SCHEMBL30765662 0.89 LMNA (0.34) ELANELMNAALDH1A1HPGDCYP2C9
SCHEMBL31558435 0.89 ELANE (0.45) ELANELMNAGABRPGABRDGABRA1
SCHEMBL30765837 0.87 KIT (0.35) HPGDCYP2C9GABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed